FDA grants orphan-drug designation for TauRx’s LMTX in frontotemporal dementia
Dec 11 - 2018 11:49 AM
TauRx today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LMTX® for the "treatment of frontotemporal dementia".
LUCIDITY Study – Protocol Amendment
Jul 20 - 2018 06:03 PM
TauRx Therapeutics Ltd has announced that it has revised the design of its LUCIDITY clinical study (Study TRx-237-039) in light of new guidance issued by the FDA
Alzheimer candidate LMTX® inhibits α-sync aggregation in pre-clinical Parkinson’s Disease study
Jan 25 - 2018 03:20 PM
TauRx Therapeutics Ltd has reported preclinical study results, published online in Frontiers in Molecular Neuroscience
Second Phase 3 Study Results for LMTX® published in the Journal of Alzheimer’s Disease
Nov 27 - 2017 12:28 PM
ABERDEEN, Scotland and Singapore, November 27, 2017 – TauRx Therapeutics Ltd today reported the full results from its second Phase 3 clinical study of LMTX®, the first tau aggregation inhibitor in Alzheimer’s disease, published online in the Journal of Alzheimer’s Disease.
TRx-237-005 Phase 3 Clinical Trial
Dec 17 - 2016 12:00 AM
Top-line results from TauRx Therapeutics Ltd.’s second Phase 3 trial in Alzheimer’s disease, study TRx-237-005, were presented at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) 2016 meeting in San Diego, CA, USA.1